We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
-16.09%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.65B
AUM Growth
-$1.07B
(-39%)
Cap. Flow
-$484M
Cap. Flow
% of AUM
-29.24%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
77
New
–
Increased
10
Reduced
34
Closed
14
Top Buys
| 1 |
Replimune Group
REPL
|
+$12.8M |
| 2 |
Cogent Biosciences
COGT
|
+$6.35M |
| 3 |
Establishment Labs
ESTA
|
+$5.01M |
| 4 |
Annexon
ANNX
|
+$4.78M |
| 5 |
Intuitive Surgical
ISRG
|
+$4.1M |
Top Sells
| 1 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$83.3M |
| 2 |
Krystal Biotech
KRYS
|
+$81.8M |
| 3 |
Abbott
ABT
|
+$29.8M |
| 4 |
Align Technology
ALGN
|
+$28.6M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$27.3M |
Sector Composition
| 1 | Healthcare | 99.13% |
| 2 | Industrials | 0.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$10.2B
| $188M | 11.34% |
1,021,078
-487,172
| -32% | -$81.8M |
|
|
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
| $105M | 6.35% |
10,595,089
-2,662,197
| -20% | -$27.3M |
|
3
Nurix Therapeutics
NRIX
$2.45B
| $92.3M | 5.58% |
4,423,616
-59,400
| -1% | -$925K |
|
4
Stoke Therapeutics
STOK
$1.83B
| $63.8M | 3.86% |
4,721,054
-351,995
| -7% | -$4.75M |
|
5
Immunome
IMNM
$2.53B
| $59.2M | 3.58% |
4,889,554
| – | – |
|
6
Regenxbio
RGNX
$622M
| $53.5M | 3.23% |
4,569,802
+18,246
| +0.4% | +$284K |
|
7
LivaNova
LIVN
$4.41B
| $51M | 3.08% |
929,506
-108,274
| -10% | -$6.17M |
|
|
8
Replimune Group
REPL
$825M
| $50.1M | 3.03% |
5,562,096
+1,832,113
| +49% | +$12.8M |
|
9
ADC Therapeutics
ADCT
$158M
| $48.3M | 2.92% |
15,269,217
| – | – |
|
10
Kymera Therapeutics
KYMR
$9.29B
| $47.1M | 2.85% |
1,579,275
-154,814
| -9% | -$5.36M |
|
11
Scholar Rock
SRRK
$6.47B
| $45.4M | 2.75% |
5,453,083
-966,527
| -15% | -$11.8M |
|
12
Zymeworks
ZYME
$1.81B
| $44.3M | 2.68% |
5,211,037
-349,761
| -6% | -$3.11M |
|
13
Fate Therapeutics
FATE
$336M
| $43.2M | 2.61% |
13,169,057
| – | – |
|
|
14
Cogent Biosciences
COGT
$6.67B
| $40.5M | 2.45% |
4,799,973
+837,371
| +21% | +$6.35M |
|
15
Beam Therapeutics
BEAM
$3.13B
| $39.9M | 2.41% |
1,703,061
-176,556
| -9% | -$4.34M |
|
|
SLN
16
Silence Therapeutics
SLN
$483M
| $38.3M | 2.31% |
2,014,296
-13,373
| -0.7% | -$284K |
|
|
AKRO
17
DELISTED
Akero Therapeutics
AKRO
| $37.9M | 2.29% |
1,614,473
-244,229
| -13% | -$5.22M |
|
18
Biohaven
BHVN
$2.22B
| $37.7M | 2.28% |
1,087,576
-75,665
| -7% | -$2.99M |
|
19
Neurogene
NGNE
$781M
| $36.9M | 2.23% |
1,013,663
+78,411
| +8% | +$2.77M |
|
20
Pliant Therapeutics
PLRX
$68.7M
| $34.5M | 2.09% |
3,209,591
+112,371
| +4% | +$1.45M |
|
|
CTLT
21
DELISTED
CATALENT, INC.
CTLT
| $33.5M | 2.02% |
595,570
-36,894
| -6% | -$2.06M |
|
|
22
Annexon
ANNX
$932M
| $31.5M | 1.9% |
6,427,462
+924,272
| +17% | +$4.78M |
|
23
Boston Scientific
BSX
$64.5B
| $30.1M | 1.82% |
390,253
-170,673
| -30% | -$12.5M |
|
24
IDEAYA Biosciences
IDYA
$3.54B
| $26.7M | 1.61% |
759,516
-163,162
| -18% | -$6.46M |
|
25
Celldex Therapeutics
CLDX
$3B
| $26.6M | 1.61% |
718,723
-177,731
| -20% | -$6.71M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO